Does NAD Plus Really Work: Evidence-Based Clinical Perspective

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ (nicotinamide adenine dinucleotide) supplementation shows promise in preclinical models for mitochondrial function and sirtuin activation, yet human clinical evidence remains limited and inconsistent. Published randomized controlled trials in humans are sparse, with most supporting data derived from animal studies or short-term observational work.

For individuals exploring NAD+ as part of a broader wellness strategy, understanding the gap between laboratory evidence and real-world outcomes is essential. PlexusDx emphasizes precision evaluation—examining genetic predispositions and biomarker context—to help you and your provider make informed decisions about whether NAD+ fits your personalized health profile.

What the Current Clinical Evidence Actually Shows

Human clinical trials on NAD+ supplementation remain limited in scope and duration. Most published studies examine surrogate markers—such as NAD+ levels in blood or muscle—rather than measurable health outcomes like strength, cognitive function, or longevity.

Animal studies demonstrate promising effects on mitochondrial biogenesis and stress resistance, but these findings have not consistently translated to human populations. A 2023 review noted that well-designed, long-term randomized controlled trials in humans are needed to establish efficacy and safety profiles for NAD+ precursors like NMN and NR.

NAD+ Metabolism and Individual Response Variability

NAD+ synthesis and utilization depend on multiple enzyme systems, including nicotinamide phosphoribosyltransferase (NAMPT) and NAD+ synthase. Genetic variation in these pathways can influence how efficiently an individual converts NAD+ precursors into active NAD+ and how cellular machinery uses it.

This variability helps explain why some individuals report subjective benefits from NAD+ supplementation while others notice minimal effect. Biomarker assessment—such as baseline NAD+ levels, mitochondrial function markers, and energy metabolism indicators—may provide context for personalized evaluation with your healthcare provider.

Factor	Clinical Relevance
NAD+ Precursors (NMN, NR, NAD+)	Oral bioavailability varies; intracellular uptake depends on transporter expression
NAMPT Enzyme Activity	Genetic variants affect NAD+ synthesis efficiency from dietary precursors
Sirtuin Expression	Individual differences in age, tissue type, and metabolic state influence sirtuin activation
Baseline Energy Status	Low mitochondrial function or ATP depletion may respond differently than healthy baseline states
Age and Metabolic Health	NAD+ declines with age; metabolic conditions may alter cellular NAD+ utilization patterns

Biomarker Context and NAD+ Supplementation Decisions

Before starting NAD+ supplementation, assessing baseline energy metabolism markers—such as mitochondrial ATP production, lactate levels, and cellular respiration indices—can help establish whether NAD+ precursor supplementation aligns with your metabolic profile.

Genetic predispositions in energy metabolism pathways may also influence how your cells respond to NAD+ supplementation. Some individuals carry genetic variants that support robust NAD+ synthesis and sirtuin function; others may have reduced capacity in these pathways, potentially affecting supplementation strategy and dosing.

Safety Profile and Who Should Approach NAD+ Cautiously

NAD+ precursors are generally well-tolerated at recommended doses, with most reported side effects being mild and transient—such as nausea, headache, or flushing. However, long-term safety data in humans remains incomplete, particularly for sustained high-dose use or in individuals with specific medical conditions.

Individuals with a history of autoimmune conditions, certain cancers, or those taking medications that affect NAD+ pathways should consult their healthcare provider before starting supplementation. Pregnancy, lactation, and pediatric populations lack adequate safety evidence and are typically contraindications for NAD+ supplementation.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines genetic variants in energy metabolism and cellular signaling pathways—including variants relevant to mitochondrial function and metabolic adaptation. These predispositions may help provide context for understanding how your body manages NAD+ synthesis and utilization, supporting a more informed conversation with your healthcare provider about whether NAD+ supplementation aligns with your genetic profile.

The genetic test reveals predispositions in peptide and metabolic pathways, not exact medication or supplement response. While NAD+ is not a peptide, understanding your genetic capacity for energy metabolism, mitochondrial efficiency, and cellular stress adaptation can contextualize NAD+ decisions. This information should be interpreted with a qualified healthcare provider to assess individual relevance.

When exploring NAD+ as part of a precision wellness plan, biomarker assessment combined with genetic context can help you and your provider evaluate whether supplementation addresses your specific metabolic needs. This personalized approach moves beyond generic supplementation toward evidence-informed decisions tailored to your physiology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Does NAD+ supplementation really increase energy and reduce fatigue?

Clinical evidence is mixed. Some short-term studies report subjective energy improvements, but long-term randomized controlled trials in humans are limited. Individual response varies based on baseline metabolic status and genetic factors. A provider can help assess whether trial use is appropriate for your situation.

What do clinical studies actually show about NAD+ and aging?

Animal studies demonstrate promising effects on mitochondrial function and lifespan. However, human clinical trials examining anti-aging outcomes are sparse and short-term. Most evidence remains preliminary, and robust long-term human safety and efficacy data are needed to support aging claims.

How can PlexusDx's genetic test relate to NAD+ supplementation decisions?

The Precision Peptide Genetic Test examines variants in energy metabolism and mitochondrial pathways that may contextualize how your body manages NAD+ synthesis and cellular energy production. This predisposition information can support a more personalized discussion with your provider about supplementation fit.

Are there side effects or safety concerns with NAD+ supplements?

NAD+ precursors are generally well-tolerated at standard doses, with mild side effects like nausea or headache reported rarely. Long-term safety data in humans is incomplete. Individuals with autoimmune conditions, certain cancers, or those on specific medications should consult their provider before use.

Can genetic testing predict whether I'll respond well to NAD+ supplementation?

Genetic testing reveals predispositions in energy metabolism pathways, not exact supplement response. While variants in NAD+ synthesis and sirtuin genes may contextualize your metabolic potential, individual response depends on multiple factors. Biomarker assessment and provider guidance remain essential for personalized evaluation.